Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Lumos Diagnostics has secured a $41.38/test reimbursement rate for its FebriDx diagnostic test from the Centers for Medicare and Medicaid Services, effective January 2025. The approval is expected to enhance accessibility and adoption of FebriDx, which helps differentiate between bacterial and viral infections, addressing antibiotic resistance concerns. This milestone is seen as a significant step in the U.S. commercialization strategy for Lumos’ innovative diagnostic solutions.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- New “Anti-Woke” ETF Targets Starbucks (NASDAQ:SBUX)
- Ford (NYSE:F) Plans New EV Plant
- The Gelsinger Post-Mortem Starts at Intel (NASDAQ:INTC)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
